News Releases

Keyword Search

2013 | 2012 | 2011 | 2010 | 2009

Date	Title
05/16/13	HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
05/10/13	HeartWare Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference to be Webcast
04/29/13	HeartWare International Reports $49.2 Million In First Quarter 2013 Revenue; 87% Increase From First Quarter Of 2012
04/15/13	HeartWare Schedules First Quarter Conference Call And Webcast
03/18/13	HeartWare International, Inc. Announces Closing of Public Offering of Common Stock
03/12/13	HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock
03/11/13	HeartWare International, Inc. Announces Public Offering of Common Stock
03/06/13	HeartWare Presentation at the Barclays Capital 2013 Global Healthcare Conference To Be Webcast
02/28/13	HeartWare Presentation At Raymond James 34th Annual Institutional Investors Conference To Be Webcast
02/27/13	HeartWare International Reports Fourth Quarter 2012 Revenue Of $32.7 Million; Full Year 2012 Revenue Of $110.9 Million
02/19/13	HeartWare Schedules Fourth Quarter Conference Call and Webcast
02/08/13	HeartWare Presentation at Leerink Swann Global Healthcare Conference to be Webcast
01/07/13	HeartWare International Announces Preliminary Fourth Quarter 2012 Revenues
01/03/13	HeartWare Presentation At The 31st Annual J.P. Morgan Healthcare Conference To Be Webcast
12/06/12	HeartWare Presentation at the Oppenheimer 23rd Annual Healthcare Conference to be Webcast
11/20/12	HeartWare Receives FDA Approval for HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation for Patients with Advanced Heart Failure
11/16/12	HeartWare Presentation At The 24th Annual Piper Jaffray Healthcare Conference To Be Webcast
11/09/12	HeartWare Reports Third Quarter 2012 Results
11/09/12	HeartWare Presentation At The Lazard Capital Markets 9th Annual Healthcare Conference To Be Webcast
11/01/12	HeartWare Schedules Third Quarter Conference Call And Webcast
09/14/12	HeartWare Presentation at the UBS Global Life Sciences Conference to be Webcast
08/10/12	HeartWare Presentation At The Canaccord Genuity 32nd Annual Growth Conference To Be Webcast
08/09/12	HeartWare Presentation at the 2012 Wedbush PacGrow Lifesciences Management Access Conference to be Webcast
08/07/12	HeartWare Reports Second Quarter 2012 Results
08/02/12	HeartWare Completes Acquisition Of World Heart Corporation
07/30/12	HeartWare Schedules Second Quarter Conference Call And Webcast
07/09/12	HeartWare Names Peter F. McAree Chief Financial Officer
05/23/12	HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure
05/23/12	HeartWare Announces Publication Of Results From U.S. Bridge-To-Transplant Clinical Trial
05/10/12	HeartWare International Reports First Quarter 2012 Revenue of $26.3 Million; 47% Increase From $18.0 Million in First Quarter 2011
05/08/12	HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
05/07/12	HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
05/03/12	Heartware Schedules First Quarter Conference Call And Webcast
04/25/12	FDA Advisory Committee Votes in Favor of HeartWare® Ventricular Assist System as Bridge to Transplant for Patients With End-Stage Heart Failure
04/25/12	HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
03/29/12	HeartWare International Expands Intellectual Property and Technology Portfolio Through Definitive Agreement to Acquire World Heart Corporation for US$8 Million
03/16/12	HeartWare Receives 54-Patient Allotment From FDA Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
03/06/12	HeartWare Presentation At The Barclays Capital 2012 Global Healthcare Conference To Be Webcast
02/16/12	HeartWare International Reports Fourth Quarter 2011 Revenues of $23.1 Million; Full Year 2011 Revenues of $82.8 Million; 50% Increase From $55.2 Million in 2010
02/14/12	HeartWare Announces Date for FDA Advisory Committee Panel
02/06/12	HeartWare Schedules Fourth Quarter Conference Call and Webcast
01/09/12	HeartWare and Dualis MedTech Announce Agreement to Develop Fully Implantable Ventricular Assist System
01/04/12	HeartWare to Webcast Presentation at the 30th Annual J.P. Morgan Healthcare Conference
12/09/11	HeartWare to Present at the Oppenheimer 22nd Annual Healthcare Conference
11/23/11	HeartWare to Present at the 23rd Annual Piper Jaffray Health Care Conference
11/10/11	HeartWare to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
11/04/11	HeartWare to Present at the Credit Suisse 2011 Healthcare Conference
10/27/11	HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010
10/27/11	HeartWare International Announces Planned Departure of Chief Financial Officer
10/21/11	HeartWare Schedules Third Quarter Conference Call and Webcast
10/02/11	HeartWare Reports Additional Clinical Data From Bridge-to-Transplant and Continued Access Patients at the 25th European Association for Cardio-Thoracic Surgery (EACTS) Meeting in Lisbon
09/28/11	HeartWare Announces Presentation of Clinical Data at the 25th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Lisbon
09/19/11	HeartWare to Present at The Lazard Capital Markets 3rd Annual Circulatory Assist Device Day
09/14/11	HeartWare to Present at the UBS Global Life Sciences Conference
09/09/11	HeartWare Completes GLP Studies of Next Generation MVAD® Pump; Data Presented Today at ISRBP Congress
08/12/11	HeartWare to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
08/08/11	HeartWare to Present at the Canaccord Genuity 31st Annual Growth Conference
08/04/11	HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010
07/27/11	HeartWare to Report Financial Results for Second Quarter of 2011
06/16/11	HeartWare to Present at the Wells Fargo 2011 Healthcare Conference
05/06/11	HeartWare to Present at the 2011 Bank of America Merrill Lynch Health Care Conference
05/05/11	HeartWare International Reports First Quarter 2011 Revenues of $18.0 Million; 68% Increase From $10.7 Million in First Quarter 2010
04/28/11	HeartWare Supplemental Addendum to CE Mark Accepted by BSI
04/26/11	HeartWare to Report 2011 First Quarter Financial Results
04/15/11	HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
04/12/11	HeartWare Announces Presentations at The International Society of Heart and Lung Transplantation Annual Meeting
03/24/11	HeartWare International Receives Approval From the Therapeutic Goods Administration (TGA) in Australia
03/07/11	HeartWare to Present at the Barclays Capital 2011 Global Healthcare Conference
02/24/11	HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009
02/15/11	HeartWare to Report 2010 Fourth Quarter and Year-End Financial Results
01/24/11	HeartWare Receives Third Patient Allotment From FDA - Authorizing 94 Additional Patients - Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
01/04/11	HeartWare to Present at the 29th Annual J.P. Morgan Healthcare Conference
12/28/10	HeartWare Files PMA Application for FDA Approval of the HeartWare(R) Ventricular Assist System for a Bridge-to-Transplant Indication
12/15/10	HeartWare International, Inc. Announces Completion of Concurrent Public Offerings of Convertible Senior Notes and Common Stock
12/10/10	HeartWare International, Inc. Announces Pricing of Concurrent Public Offerings of Convertible Senior Notes and Common Stock
12/09/10	HeartWare International, Inc. Announces Concurrent Public Offerings of Convertible Senior Notes and Common Stock
12/02/10	HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity Conference
11/18/10	HeartWare to Present at the 22nd Annual Piper Jaffray Health Care Conference
11/14/10	HeartWare Achieves Primary Endpoint with 92% Success in Pivotal Bridge-to-Transplant Clinical Trial, ADVANCE
11/11/10	HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
11/09/10	HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010
11/03/10	HeartWare International Reports Third Quarter 2010 Revenues of $13.8 Million; Compared to $7.5 Million in Third Quarter of 2009
10/20/10	HeartWare to Report Financial Results for Third Quarter of 2010
09/23/10	Appendix 3B
09/23/10	HeartWare to Present at Lazard Capital Markets Circulatory Assist Device Day
09/15/10	HeartWare to Present at the UBS 2010 Global Life Sciences Conference
09/03/10	HeartWare Receives Second Patient Allotment Under Continued Access Protocol for Pivotal U.S. Bridge-To-Transplant Clinical Trial
08/05/10	HeartWare International Reports Second Quarter 2010 Revenues of $9.8 Million; Compared to $3.0 Million in Second Quarter 2009
08/04/10	HeartWare to Present at The Canaccord Genuity 30th Annual Growth Conference
07/29/10	HeartWare to Present at the Wedbush Securities 2010 Life Sciences Best Ideas Conference
07/27/10	HeartWare to Report Financial Results for Second Quarter of 2010
06/24/10	HeartWare Announces Board Succession
06/17/10	HeartWare to Present at the Wells Fargo Securities 2010 Healthcare Conference
06/14/10	HeartWare Receives Conditional FDA Approval to Commence Pivotal Destination Therapy Clinical Trial in the U.S.
05/06/10	HeartWare to Present at Bank of America Merrill Lynch Health Care Conference in New York
05/03/10	HeartWare International Reports First Quarter 2010 Revenues of $10.7 Million; Compared With $1.5 Million In First Quarter 2009
04/26/10	HeartWare Initiates Repairs and Partial Recall of Controllers
04/23/10	HeartWare Data From First 100 Patients in International Clinical and Commercial Experience Shows 90% Survival at 180 Days
04/12/10	HeartWare to Report Financial Results for First Quarter of 2010
04/07/10	HeartWare Receives FDA Approval of Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
03/11/10	HeartWare to Present at the Barclays Capital 2010 Global Healthcare Conference
03/04/10	HeartWare to Present at the Roth Capital Partners OC Growth Stock Conference
02/22/10	HeartWare International Reports Fourth Quarter Revenues of $12.2 Million; Full Year 2009 Revenues of $24.2 Million
02/22/10	HeartWare Announces Early Conclusion of Enrollment for U.S. Bridge-to-Transplant Clinical Trial
02/08/10	HeartWare to Report 2009 Fourth Quarter and Year-End Financial Results
02/02/10	HeartWare International, Inc. Announces Completion of Public Offering of Common Stock
01/27/10	HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock
01/26/10	HeartWare International, Inc. Announces Commencement of Public Offering of Common Stock
01/06/10	HeartWare to Present at J.P. Morgan Healthcare Conference in San Francisco
11/25/09	HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City
11/06/09	HeartWare to Present at Upcoming Investment Conferences in November
11/04/09	HeartWare International Reports Third Quarter Revenues of $7.5 Million
10/29/09	Advance Notice of Q3 Earnings Call
10/05/09	U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
09/01/09	HeartWare International, Inc. Temporary Suspension of Trading
08/20/09	HeartWare International Surpasses 50 Implants in the US
08/17/09	HeartWare International, Inc. Closes US$60 Million Financing
08/11/09	HeartWare to Present at Canaccord Adams 29th Annual Global Growth Conference
08/10/09	HeartWare International, Inc. Announces US$55 Million Financing
07/31/09	Thoratec Corporation and HeartWare International, Inc. Announce Termination of Proposed Transaction
07/29/09	U.S. Federal Trade Commission to Challenge Thoratec's Proposed Acquisition of HeartWare International
05/12/09	HeartWare to Present at Eighth Annual JMP Securities Research Conference
04/24/09	HeartWare International Clinical Trial Shows 90% Survival at 180 Days